Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LILLY BUYING SERAGEN IL-2 FUSION TOXIN CANCER RIGHTS FOR UP TO $45 MIL.

Executive Summary

LILLY BUYING SERAGEN IL-2 FUSION TOXIN CANCER RIGHTS FOR UP TO $45 MIL. under a letter of intent announced July 15. The proposed agreement gives Lilly development, distribution and marketing rights to Hopkinton, Mass.-based Seragen's interleukin-2 fusion toxins worldwide except in "certain Asian countries." Under the terms of a December 1993 letter of intent, the Japanese firm Ajinomoto has the option to become Seragen's partner for development and marketing of IL-2 fusion toxin in Japan, China, Taiwan and Korea.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel